PER 0.00% 7.8¢ percheron therapeutics limited

Ann: Long COVID-19 strategic collaboration with US Experts, page-102

  1. 4,331 Posts.
    lightbulb Created with Sketch. 2022
    https://www.medscape.com/viewarticle/974840

    https://www.frontiersin.org/articles/10.3389/fimmu.2018.01617/full

    https://musculardystrophynews.com/2020/05/26/phase-2-trial-supports-atl1102-safety-improving-muscle-strength-function-dmd-boys/


    The first link shows the effect of long covid, and also the biomarkers that have been found associated with long covid.

    The second link shows how cd49 and cd4 act on Bcells and inflammation.

    The third link shows results from the DMD trial, highlighting how ATL1102 prevents the over expression of cd49. This is the mode of operation that is hoped to treat ling covid.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
0.000(0.00%)
Mkt cap ! $70.32M
Open High Low Value Volume
7.8¢ 7.9¢ 7.8¢ $16.54K 212.7K

Buyers (Bids)

No. Vol. Price($)
1 6454 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 12975 1
View Market Depth
Last trade - 16.10pm 23/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.